IL6 and COVID-19: Inhibition of the cytokine interleukin 6 (IL-6) using drugs such as tocilizumab, which bind to the IL-6 receptor, has been shown to reduce mortality in critically unwell patients with Coronavirus Disease 2019 (COVID-19).